Triple Combination Therapy for Crohn's Disease Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Crohn's disease, particularly for patients at high risk of complications, have limited effectiveness in achieving remission and modifying disease progression, with approximately 40% of patients not responding to combination therapy with TNF-antagonist and immunomodulator regimens.
Innovation Solution
A triple combination therapy involving a humanized anti-α4β7 antibody, such as vedolizumab, a TNF antagonist like adalimumab, and an immunomodulator like methotrexate, administered according to specific dosing regimens to achieve endoscopic remission and reduce disease progression in high-risk Crohn's disease patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with TNF-antagonist and immunomodulator is used, then treatment efficacy is improved, but remission rate remains insufficient (only about 60% of patients achieve remission)
Solution Approach 1:
The patent combines three medications (TNF-antagonist, immunomodulator, and anti-a4p7 antibody) into a triple combination therapy regimen. This merging of multiple therapeutic agents with different mechanisms of action aims to achieve synergistic effects, thereby improving the remission rate from the conventional 60% to a higher percentage of patients achieving remission.
2Reliability
If conventional combination therapy is used, then disease progression is partially controlled, but structural complications still develop in 33.7% of patients at 5 years
Solution Approach 1:
The patent implements early intervention by initiating triple combination therapy at the time of diagnosis for high-risk patients. This preliminary action aims to prevent disease progression and structural complications (strictures, fistulas) before they develop, rather than treating them after they arise. The anti-a4p7 antibody component specifically targets intestinal inflammation to prevent structural damage.
3Productivity
If triple combination therapy is administered, then remission rate and disease progression modification are improved, but treatment complexity and dosing regimen requirements increase
Solution Approach 1:
The patent segments the triple combination therapy into distinct dosing phases: an initial phase with higher doses of all three medications, followed by a maintenance phase with reduced doses. This segmentation of the treatment timeline into different phases with specific dosing requirements simplifies the overall regimen while maintaining high remission rates. The structured approach makes the complex triple therapy more manageable for both patients and clinicians.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The triple combination therapy significantly improves remission rates and modifies disease progression, achieving endoscopic remission and long-term clinical benefits for high-risk Crohn's disease patients by targeting the α4β7 integrin pathway and reducing inflammation.
Implementation Method 1
The anti-a4p7 antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, the humanized antibody has binding specificity for the α4β7 complex
Implementation Method 2
a TNF antagonist like adalimumab
Implementation Method 3
an immunomodulator like methotrexate
Data Source
AI summary
The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.